Cerebrolysin

Stroke A 2023 review indicated that cerebrolysin or cerebrolysin-like peptide mixtures from cattle brain likely provide no benefit for preventing all-cause death in acute ischemic stroke, and that higher quality studies are needed. A 2020 study suggested a lack of benefit in hemorrhagic stroke related to cerebral aneurysm. Dementia Reviews of preliminary research indicate a possible improvement in cognitive function using cerebrolysin for vascular dementia and Alzheimer's disease, although further high-quality research is needed. Other Early studies have suggested potential use of cerebrolysin with a wide variety of neurodegenerative disorders, including traumatic brain injury, schizophrenia, multiple sclerosis, cerebral palsy and spinal cord injury although research is still preliminary. ==Adverse effects==

Upon injection, adverse effects of cerebrolysin include nausea, dizziness, headache, and sweating. It is not recommended for use in people with epilepsy, kidney disease, or hypersensitivity to the compound constituents. In trials studying the use of cerebrolysin after acute stroke, there was no increased risk of "serious adverse events" requiring hospitalization. These were specifically defined as "...any untoward medical occurrence that, at any dose, resulted in death, [was] life-threatening, required inpatient hospitalisation or resulted in prolongation of existing hospitalisation, resulted in persistent or significant disability/incapacity, [was] a congenital anomaly/birth defect, or [was] a medically important event or reaction". ==Pharmacology==

Laboratory studies indicate there may be neurotrophic effects of cerebrolysin similar to endogenous mechanisms, although its specific molecular effects are not clear. Cerebrolysin is given by injection. ==Regulatory==

Although cerebrolysin is used in Russia, Eastern European countries, China, and other Asian countries, its status as a government-approved drug is unclear. == References ==